Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 223 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: autologous bone marrow transplantation Clear all
Completed Phase 1Phase 2 Interventional

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer

NCT00002509
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, mesna, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Temple University
Other
Eligibility
15 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2010 · Synced Oct 2, 2026, 4:23 PM EDT
Not listed Phase 1 Interventional

Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer

NCT00004086
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, cisplatin, cytarabine, etoposide, ifosfamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 LL2 IgG, yttrium Y 90 epratuzumab
Biological · Drug · Procedure + 1 more
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Belleville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2009 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Results available

Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)

NCT00203203
View directory record Official record
Conditions
Ischemic Cardiomyopathy
Interventions
Intramyocardial Injection of stem cells via NOGA Mapping, Control, then Stem Cell Therapy
Device · Other
Lead sponsor
Texas Heart Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 2, 2026, 4:23 PM EDT
Active, not recruiting Phase 1 Interventional

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

NCT05095532
View directory record Official record
Conditions
Chronic Pancreatitis, Mesenchymal Stem Cells
Interventions
Bone marrow-derived mesenchymal stem cells, Placebo
Biological · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia

NCT00416598
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Untreated Adult Acute Myeloid Leukemia
Interventions
Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cytarabine, Daunorubicin Hydrochloride, Decitabine, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Pharmacological Study
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 59 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
46
States / cities
San Francisco, California • Lewes, Delaware • Newark, Delaware + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional

Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer

NCT00004048
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, doxorubicin hydrochloride, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Drug · Procedure + 1 more
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
16 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Belleville, New Jersey • Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 2, 2026, 4:23 PM EDT
Not yet recruiting Not applicable Interventional

Allograft vs. Autograft Nonunion

NCT07310082
View directory record Official record
Conditions
Nonunion Fracture
Interventions
Autograft, Allograft
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Melphalan in Children

NCT02390544
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Melphalan
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 2, 2026, 4:23 PM EDT
Withdrawn Not applicable Interventional

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

NCT01795430
View directory record Official record
Conditions
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions
etoposide, ifosfamide, intensity-modulated radiation therapy, topotecan hydrochloride, busulfan, melphalan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, autologous bone marrow transplantation
Drug · Radiation · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma

NCT00002221
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Peripheral blood stem cells
Drug
Lead sponsor
Ribozyome
Industry
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

NCT00002474
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cyclophosphamide, mitoxantrone hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support
Drug · Procedure
Lead sponsor
Loyola University
Other
Eligibility
Up to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2005
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

NCT02955550
View directory record Official record
Conditions
Multiple Myeloma
Interventions
rhIL-2, PNK-007
Drug · Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis

NCT00002810
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Temple University
Other
Eligibility
16 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2010 · Synced Oct 2, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

NCT00632827
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection, Granulocyte-colony stimulating factor (G-CSF), Pegfilgrastim, Cyclophosphamide, Vincristine, Leucovorin, Methotrexate, Doxorubicin Hydrochloride, Cytarabine, Etoposide, Carmustine, Denileukin diftitox
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

NCT04402138
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Denver, Colorado • New Orleans, Louisiana • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 2Phase 3 Interventional

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

NCT00070187
View directory record Official record
Conditions
Lymphoma
Interventions
aldesleukin, filgrastim, recombinant interferon gamma, carmustine, cyclosporine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2013 · Synced Oct 2, 2026, 4:23 PM EDT
Recruiting Phase 3 Interventional

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

NCT06724237
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
164
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 2, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional Results available

S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma

NCT00121186
View directory record Official record
Conditions
Lymphoma
Interventions
fludarabine phosphate, melphalan, methotrexate, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
33
States / cities
Maywood, Illinois • Beech Grove, Indiana • Richmond, Indiana + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 2, 2026, 4:23 PM EDT
Terminated Not applicable Interventional Results available

Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)

NCT01927718
View directory record Official record
Conditions
Myeloma
Interventions
Thalidomide, Lenalidomide, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

NCT00083135
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, iobenguane I 131
Biological · Procedure · Radiation
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Not applicable Interventional

Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation

NCT04739930
View directory record Official record
Conditions
Cartilage Injury
Interventions
Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation, Control group incision
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Not applicable Interventional Results available

BMAC & Allograft vs BMP-2

NCT02924571
View directory record Official record
Conditions
Spinal Fusion
Interventions
Bone Marrow Aspirate Concentrate (BMAC) + Allograft, Recombinant Human Bone Morphogenetic Protein-2 (BMP), Autograft
Device · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00004899
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, busulfan, etoposide, autologous bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 2, 2026, 4:23 PM EDT
Completed Phase 2 Interventional

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

NCT00002634
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, monoclonal antibody 3F8, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, mesna, perfosfamide, vincristine sulfate, autologous bone marrow transplantation, in vitro-treated bone marrow transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy, radioisotope therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 2, 2026, 4:23 PM EDT